登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，9月9日，De novo design of picomolar SARS-CoV-2 miniprotein inhibitors》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-09-16

  • De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
    View ORCID ProfileLongxing Cao1,2, Inna Goreshnik1,2, View ORCID ProfileBrian Coventry1,2,3, View ORCID ProfileJames Brett Case4, View ORCID ProfileLauren Miller1,2, Lisa Kozodoy1,2, Rita E. Chen4,5, View ORCID ProfileLauren Carter1,2, View ORCID ProfileAlexandra C. Walls1, Young-Jun Park1, View ORCID ProfileEva-Maria Strauch6, View ORCID ProfileLance Stewart1,2, View ORCID ProfileMichael S. Diamond4,7, View ORCID ProfileDavid Veesler1, View ORCID ProfileDavid Baker1,2,8,*
    See all authors and affiliations

    Science  09 Sep 2020:
    eabd9909
    DOI: 10.1126/science.abd9909

    Abstract
    Targeting the interaction between the SARS-CoV-2 Spike protein and the human ACE2 receptor is a promising therapeutic strategy. We designed inhibitors using two de novo design approaches. Computer generated scaffolds were either built around an ACE2 helix that interacts with the Spike receptor binding domain (RBD), or docked against the RBD to identify new binding modes, and their amino acid sequences designed to optimize target binding, folding and stability. Ten designs bound the RBD with affinities ranging from 100pM to 10nM, and blocked ARS-CoV-2 infection of Vero E6 cells with IC 50 values between 24 pM and 35 nM; The most potent, with new binding modes, are 56 and 64 residue proteins (IC 50 ~ 0.16 ng/ml). Cryo-electron microscopy structures of these minibinders in complex with the SARS-CoV-2 spike ectodomain trimer with all three RBDs bound are nearly identical to the computational models. These hyperstable minibinders provide starting points for SARS-CoV-2 therapeutics.

  • 原文来源：https://science.sciencemag.org/content/early/2020/09/08/science.abd9909
107浏览量
原文链接
相关报告

  • 《Science Signaling，9月29日，High-resolution structures of the SARS-CoV-2 2′-O-methyltransferase reveal strategies for structure-based inhibitor design》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-10-14
    • High-resolution structures of the SARS-CoV-2 2′-O-methyltransferase reveal strategies for structure-based inhibitor design View ORCID ProfileMonica Rosas-Lemus1,2,*, View ORCID ProfileGeorge Minasov1,2,*, View ORCID ProfileLudmilla Shuvalova1,2,*, View ORCID ProfileNicole L. Inniss1,2, View ORCID ProfileOlga Kiryukhina1,2, View ORCID ProfileJoseph Brunzelle3, and View ORCID ProfileKarla J. F. Satchell1,2,† See all authors and affiliations Science Signaling  29 Sep 2020: Vol. 13, Issue 651, eabe1202 DOI: 10.1126/scisignal.abe1202 Abstract There are currently no antiviral therapies specific for SARS-CoV-2, the virus responsible for the global pandemic disease COVID-19. To facilitate structure-based drug design, we conducted an x-ray crystallographic study of the SARS-CoV-2 nsp16-nsp10 2′-O-methyltransferase complex, which methylates Cap-0 viral mRNAs to improve viral protein translation and to avoid host immune detection. We determined the structures for nsp16-nsp10 heterodimers bound to the methyl donor S-adenosylmethionine (SAM), the reaction product S-adenosylhomocysteine (SAH), or the SAH analog sinefungin (SFG). We also solved structures for nsp16-nsp10 in complex with the methylated Cap-0 analog m7GpppA and either SAM or SAH. Comparative analyses between these structures and published structures for nsp16 from other betacoronaviruses revealed flexible loops in open and closed conformations at the m7GpppA-binding pocket. Bound sulfates in several of the structures suggested the location of the ribonucleic acid backbone phosphates in the ribonucleotide-binding groove. Additional nucleotide-binding sites were found on the face of the protein opposite the active site. These various sites and the conserved dimer interface could be exploited for the development of antiviral inhibitors.
    52浏览量
    原文链接

  • 《Science，4月24日，Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-25
    • Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Linlin Zhang1,2, Daizong Lin1,3, Xinyuanyuan Sun1,2, Ute Curth4, Christian Drosten5, Lucie Sauerhering6,7, Stephan Becker6,7, Katharina Rox8,9, Rolf Hilgenfeld1,2,* See all authors and affiliations Science 24 Apr 2020: Vol. 368, Issue 6489, pp. 409-412 DOI: 10.1126/science.abb3405 Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (Mpro, also called 3CLpro) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 Mpro and its complex with an α-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 Mpro. The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.
    117浏览量
    原文链接